Difference between revisions of "Perifosine (KRX-0401)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== AKT and PI3K inhibitor ==Preliminary data== ===Hodgkin lymphoma=== # Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Mortarini R, Viviani S,...") |
m |
||
| Line 16: | Line 16: | ||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
[[Category:AKT1 inhibitors]] | [[Category:AKT1 inhibitors]] | ||
| − | [[Category: | + | [[Category:PI3K inhibitors]] |
[[Category:Investigational]] | [[Category:Investigational]] | ||
[[Category:Orphan drug]] | [[Category:Orphan drug]] | ||
Revision as of 17:00, 14 November 2014
Mechanism of action
AKT and PI3K inhibitor
Preliminary data
Hodgkin lymphoma
- Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Mortarini R, Viviani S, Russo D, Marchianò A, Sorasio R, Dodero A, Farina L, Giordano L, Di Nicola M, Anichini A, Corradini P, Gianni AM. Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases. Clin Cancer Res. 2014 Sep 19. [Epub ahead of print] link to original article PubMed
History of changes in FDA indication
- 9/3/2009: Received FDA orphan drug designation for treatment of multiple myeloma.
- 7/9/2010: Received FDA orphan drug designation for treatment of neuroblastoma.